Literature DB >> 6178524

Uridine rescue from the lethal toxicity of 5-fluorouracil in mice.

P Klubes, I Cerna, M A Meldon.   

Abstract

To determine the relationship between 5-fluorouracil (FUra) toxicity and its RNA- and DNA-directed actions we examined the ability of continuous SC infusions with uridine (Urd), thymidine (dThd), or deoxyuridine (dUrd) to rescue mice from the lethal toxicity of FUra. Male B6D2F1 mice were treated with a single IP injection of FUra (800 mg/kg) followed in 24 h by a 5-day infusion with either 0.9% NaCl or Urd (0.1, 1, 5, or 10 g/kg/day). Survivors were then followed up for 30 days after FUra treatment. Urd (1, 5, or 10 g/kg/day) rescued mice from the lethal toxicity of FUra, whereas Urd (0.1 g/kg/day) was as ineffective as 0.9% NaCl as a rescue agent. With variable doses of FUra followed in 24 h by a Urd infusion (5 g/kg/day) for 5 days. Urd rescued mice treated with FUra (400, 600, or 800 mg/kg) but was ineffective against higher doses of FUra (1,000 or 1,200 mg/kg). Mice treated with FUra (800 mg/kg) followed in 24 h by a 5-day infusion with either dThd (1, 5, or 10 g/kg/day) or a dUrd (1 or 5 g/kg/day) could not be rescued from the lethal toxicity of FUra. In all experiments deaths occurred between 6 and 12 days after FUra. These results, which demonstrate a specificity for Urd, but not for either dThd or dUrd, for rescuing mice from the lethal toxicity of FUra, suggest the importance of the RNA- rather than the DNA-directed actions of FUra as a determinant of its toxicity in mice.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6178524     DOI: 10.1007/BF00292865

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  24 in total

1.  Augmentation by thymidine of the incorporation and distribution of 5-fluorouracil in ribosomal RNA.

Authors:  C K Carrico; R I Glazer
Journal:  Biochem Biophys Res Commun       Date:  1979-04-13       Impact factor: 3.575

2.  Thymidylate synthetase: mechanism of inhibition by 5-fluoro-2'-deoxyuridylate.

Authors:  R J Langenbach; P V Danenberg; C Heidelberger
Journal:  Biochem Biophys Res Commun       Date:  1972-09-26       Impact factor: 3.575

3.  The physiological disposition of 5-fluorouracil in mice bearing solid L1210 lymphocytic leukemia.

Authors:  M Chadwick; W I Rogers
Journal:  Cancer Res       Date:  1972-05       Impact factor: 12.701

4.  Reversal of toxicity and antitumor activity of N-(phosphonacetyl)-L-aspartate by uridine or carbamyl-DL-asparate in vivo.

Authors:  R K Johnson
Journal:  Biochem Pharmacol       Date:  1977-01-01       Impact factor: 5.858

Review 5.  The pharmacology of the fluoropyrimidines.

Authors:  C E Myers
Journal:  Pharmacol Rev       Date:  1981-03       Impact factor: 25.468

6.  Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate.

Authors:  D V Santi; C S McHenry; H Sommer
Journal:  Biochemistry       Date:  1974-01-29       Impact factor: 3.162

7.  Potentiation of the anti-tumor activity of 5FU by thymidine and its correlation with the formation of (5FU)RNA.

Authors:  S Spiegelman; R Nayak; R Sawyer; R Stolfi; D Martin
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

8.  Nucleotide formation as adeterminant of 5-fluorouracil response in mouse leukemias.

Authors:  D Kessel; T C Hall; I Wodinsky
Journal:  Science       Date:  1966-11-18       Impact factor: 47.728

9.  Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation.

Authors:  T M Woodcock; D S Martin; L A Damin; N E Kemeny; C W Young
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

10.  Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a Phase I trial.

Authors:  J M Kirkwood; W Ensminger; A Rosowsky; N Papathanasopoulos; E Frei
Journal:  Cancer Res       Date:  1980-01       Impact factor: 12.701

View more
  16 in total

1.  Tissue distribution of [18F]-5-fluorouracil in mice: effects of route of administration, strain, tumour and dose.

Authors:  G W Visser; G C Gorree; G J Peters; J D Herscheid
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine.

Authors:  D S Martin; R L Stolfi; R C Sawyer
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites.

Authors:  G J Peters; C J van Groeningen; E J Laurensse; J Lankelma; A Leyva; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS.

Authors:  M Wasif Saif; Kostas Syrigos; Ranee Mehra; Lori K Mattison; Robert B Diasio
Journal:  Pak J Med Sci       Date:  2007       Impact factor: 1.088

5.  Effect of pyrimidine nucleosides on body temperatures of man and rabbit in relation to pharmacokinetic data.

Authors:  G J Peters; C J van Groeningen; E Laurensse; I Kraal; A Leyva; J Lankelma; H M Pinedo
Journal:  Pharm Res       Date:  1987-04       Impact factor: 4.200

6.  Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence.

Authors:  Jonathan R Brody; Tomas Hucl; Christina L Costantino; James R Eshleman; Eike Gallmeier; Heng Zhu; Michiel S van der Heijden; Jordan M Winter; Agnieszka K Wikiewicz; Charles J Yeo; Scott E Kern
Journal:  Cancer Res       Date:  2009-01-20       Impact factor: 12.701

7.  Effects of 5-benzylacyclouridine, an inhibitor of uridine phosphorylase, on the pharmacokinetics of uridine in rhesus monkeys: implications for chemotherapy.

Authors:  J P Sommadossi; E M Cretton; L B Kidd; H M McClure; D C Anderson; M H el Kouni
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  Biochemical consequences of 5-fluorouracil gastrointestinal toxicity in rats; effect of high-dose uridine.

Authors:  J Kralovanszky; N Prajda; S Kerpel-Fronius; T Bagrij; E Kiss; G J Peters
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Effect of Uridine on the Metabolism of 5-Fluorouracil in the CD8F 1 Murine Mammary Carcinoma System.

Authors:  R C Sawyer; R L Stolfi; S Spiegelman; D S Martin
Journal:  Pharm Res       Date:  1984-03       Impact factor: 4.200

10.  Schedule-dependency of in vivo modulation of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma.

Authors:  J C Nadal; C J van Groeningen; H M Pinedo; G J Peters
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.